ROMJF
Price
$0.41
Change
+$0.01 (+2.50%)
Updated
Oct 16 closing price
Capitalization
26.3M
Intraday Buy/Sell Signals
SGIOY
Price
$7.93
Change
-$0.05 (-0.63%)
Updated
Oct 16 closing price
Capitalization
13.52B
10 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ROMJF vs SGIOY

Header iconROMJF vs SGIOY Comparison
Open Charts ROMJF vs SGIOYBanner chart's image
Rubicon Organics
Price$0.41
Change+$0.01 (+2.50%)
Volume$55.24K
Capitalization26.3M
Shionogi & Co
Price$7.93
Change-$0.05 (-0.63%)
Volume$123.03K
Capitalization13.52B
ROMJF vs SGIOY Comparison Chart in %
ROMJF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGIOY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ROMJF vs. SGIOY commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ROMJF is a Hold and SGIOY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (ROMJF: $0.41 vs. SGIOY: $7.93)
Brand notoriety: ROMJF and SGIOY are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ROMJF: 105% vs. SGIOY: 183%
Market capitalization -- ROMJF: $26.3M vs. SGIOY: $13.52B
ROMJF [@Pharmaceuticals: Generic] is valued at $26.3M. SGIOY’s [@Pharmaceuticals: Generic] market capitalization is $13.52B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.85B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ROMJF’s FA Score shows that 0 FA rating(s) are green whileSGIOY’s FA Score has 1 green FA rating(s).

  • ROMJF’s FA Score: 0 green, 5 red.
  • SGIOY’s FA Score: 1 green, 4 red.
According to our system of comparison, ROMJF is a better buy in the long-term than SGIOY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ROMJF’s TA Score shows that 3 TA indicator(s) are bullish while SGIOY’s TA Score has 4 bullish TA indicator(s).

  • ROMJF’s TA Score: 3 bullish, 4 bearish.
  • SGIOY’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ROMJF is a better buy in the short-term than SGIOY.

Price Growth

ROMJF (@Pharmaceuticals: Generic) experienced а -2.94% price change this week, while SGIOY (@Pharmaceuticals: Generic) price change was -2.06% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.01%. For the same industry, the average monthly price growth was +4.92%, and the average quarterly price growth was +52.54%.

Reported Earning Dates

SGIOY is expected to report earnings on Oct 27, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.01% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SGIOY($13.5B) has a higher market cap than ROMJF($26.3M). ROMJF has higher P/E ratio than SGIOY: ROMJF (56.33) vs SGIOY (12.02). ROMJF YTD gains are higher at: 24.175 vs. SGIOY (13.938). SGIOY has higher annual earnings (EBITDA): 206B vs. ROMJF (4.43M). SGIOY has more cash in the bank: 576B vs. ROMJF (7.28M). ROMJF has less debt than SGIOY: ROMJF (9.51M) vs SGIOY (11.7B). SGIOY has higher revenues than ROMJF: SGIOY (419B) vs ROMJF (55.1M).
ROMJFSGIOYROMJF / SGIOY
Capitalization26.3M13.5B0%
EBITDA4.43M206B0%
Gain YTD24.17513.938173%
P/E Ratio56.3312.02469%
Revenue55.1M419B0%
Total Cash7.28M576B0%
Total Debt9.51M11.7B0%
FUNDAMENTALS RATINGS
ROMJF vs SGIOY: Fundamental Ratings
ROMJF
SGIOY
OUTLOOK RATING
1..100
7057
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
20
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4862
P/E GROWTH RATING
1..100
4987
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SGIOY's Valuation (20) in the null industry is somewhat better than the same rating for ROMJF (69). This means that SGIOY’s stock grew somewhat faster than ROMJF’s over the last 12 months.

SGIOY's Profit vs Risk Rating (100) in the null industry is in the same range as ROMJF (100). This means that SGIOY’s stock grew similarly to ROMJF’s over the last 12 months.

SGIOY's SMR Rating (100) in the null industry is in the same range as ROMJF (100). This means that SGIOY’s stock grew similarly to ROMJF’s over the last 12 months.

ROMJF's Price Growth Rating (48) in the null industry is in the same range as SGIOY (62). This means that ROMJF’s stock grew similarly to SGIOY’s over the last 12 months.

ROMJF's P/E Growth Rating (49) in the null industry is somewhat better than the same rating for SGIOY (87). This means that ROMJF’s stock grew somewhat faster than SGIOY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ROMJFSGIOY
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
63%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
60%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
56%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
58%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 11 days ago
72%
Bullish Trend 12 days ago
66%
Declines
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 8 days ago
57%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
65%
Aroon
ODDS (%)
Bullish Trend 5 days ago
77%
Bearish Trend 2 days ago
56%
View a ticker or compare two or three
Interact to see
Advertisement
ROMJF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGIOY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MYCG25.100.02
+0.06%
SPDR SSGA My2027 Corporate Bond ETF
VFL10.32-0.01
-0.10%
abrdn National Municipal Income Fund
EIM9.89-0.03
-0.30%
Eaton Vance Municipal
FLOW33.74-0.37
-1.07%
Global X U.S. Cash Flow Kings 100 ETF
DFSV31.09-0.62
-1.96%
Dimensional US Small Cap Value ETF

ROMJF and

Correlation & Price change

A.I.dvisor tells us that ROMJF and SGIOF have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ROMJF and SGIOF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ROMJF
1D Price
Change %
ROMJF100%
+2.58%
SGIOF - ROMJF
8%
Poorly correlated
N/A
SGIOY - ROMJF
8%
Poorly correlated
-0.63%
RSCI - ROMJF
5%
Poorly correlated
N/A
TEVJF - ROMJF
4%
Poorly correlated
N/A
PCLOF - ROMJF
3%
Poorly correlated
-0.43%
More

SGIOY and

Correlation & Price change

A.I.dvisor indicates that over the last year, SGIOY has been loosely correlated with TAK. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if SGIOY jumps, then TAK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SGIOY
1D Price
Change %
SGIOY100%
-0.63%
TAK - SGIOY
40%
Loosely correlated
+0.14%
ESAIY - SGIOY
36%
Loosely correlated
N/A
KMDA - SGIOY
27%
Poorly correlated
+2.27%
SCYX - SGIOY
23%
Poorly correlated
-1.23%
SUPN - SGIOY
22%
Poorly correlated
+0.99%
More